Lukas Krauss
Goettingen, NI, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Targeting PRMT5 Inhibitor-Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam.
Targeting PRMT5 Inhibitor-Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam.
Journal: Cancer research communications
Published: October 27, 2025
SeqCAT: Sequence Conversion and Analysis Toolbox.
Journal: Nucleic acids research
Published: March 23, 2024
Corrigendum to "A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer" [Bioorgan. Chem. 119 (2022) 105505].
Journal: Bioorganic chemistry
Published: March 08, 2024
KRASG 12C-inhibitor-based combination therapies for pancreatic cancer: insights from drug screening.
KRASG 12C-inhibitor-based combination therapies for pancreatic cancer: insights from drug screening.
Journal: Molecular oncology
Published: November 03, 2023
A Novel AMPK Inhibitor Sensitizes Pancreatic Cancer Cells to Ferroptosis Induction.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: October 13, 2023
Epigenetic control of pancreatic cancer metastasis.
Journal: Cancer metastasis reviews
Published: May 22, 2023
Development of Pyrazine-Anilinobenzamides as Histone Deacetylase HDAC1-3 Selective Inhibitors and Biological Testing Against Pancreas Cancer Cell Lines.
Journal: Methods in molecular biology (Clifton, N.J.)
Published: October 18, 2022
AP1/Fra1 confers resistance to MAPK cascade inhibition in pancreatic cancer.
Journal: Cellular and molecular life sciences : CMLS
Published: May 25, 2022
Indirect targeting of MYC sensitizes pancreatic cancer cells to mechanistic target of rapamycin (mTOR) inhibition.
Journal: Cancer communications (London, England)
Published: September 04, 2021
A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer.
Journal: Bioorganic chemistry
Published: June 22, 2021
Last Updated: 09/26/2026